MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection

Abstract

Background and ObjectivesHepatocellular carcinoma (HCC) is the fourth leading cause of cancer associated death globally. Serum micro RNAs are full of potential as noninvasive biomarkers. Here, we aim to assess the performance of serum MicroRNA-155 and MicroRNA-665 as diagnostic biomarker for HCC comparing to AFP.MethodsSerum samples were collected from 200 subjects (40 healthy control, 80 chronic hepatitis C patients with cirrhosis and without HCC (LC) and 80 HCC patients currently infected by hepatitis C infection and didn’t start the treatment). The HCC patients didn’t include alcoholic liver disease, nonalcoholic fatty liver disease nor autoimmune liver disease. MicroRNA-155 and MicroRNA-665 expression were measured by real-time quantitative PCR (RT-qPCR), while AFP level was assessed by ELISA method.ResultsBoth miR-155 and miR-665 were significantly elevated in HCC group as compared to both control and LC groups. The comparison between LC and HCC patients revealed that the serum level of miR-155 was a significant increase in HCC patients compared to LC patients; however, the serum level of miR-665 didn’t show any significant difference between the same two groups. MiR-665 expression level showed a direct correlation with tumor size in HCC patients.ConclusionsUsing measurement against AFP level in serum, miR-665 is considered a promising serum biomarker for the diagnosis of HCC patients among the LC patients without HCC. MiR-155 didn’t provide a better performance than serum AFP as a diagnostic biomarker among the same group. MiR-665 may serve as a good indicator for HCC prognosis.

Serum Exosomal lncRNA AC007099.1 Regulates the Expression of Neuropeptide-Related FAP, as a Potential Biomarker for Hepatocarcinogenesis

“…The lncRNA AC007099.1 was found to be differentially expressed in hepatocellular carcinoma exosomes. miRNA is an important risk marker for HCC and liver injury [ 40 , 41 ]. When lncRNAs and mRNAs have the same microRNA response element (MRE), there is competition between them for the same kind of miRNA.…”

Lung adenocarcinoma-specific three-integrin signature contributes to poor outcomes by metastasis and immune escape pathways

“…[ 16 , 17 ] The immune signature identified novel targets and was exploited for immunotherapies to predict the benefit of immunotherapeutic drugs. [ 18 - 20 ] Currently, noncoding RNA is also being reported as an effective cancer biomarker; [ 21 ] these signatures provided clues for both precise individual clinical treatment and drug development and also provided the basis for the inclusion and exclusion criteria of the population for clinical trials of new targeted drugs. In the present study, we focused on the ITG family, which is considered as one of the important families for cellular biological behaviors; [ 22 , 23 ] however, our results demonstrated that only ITGA5, ITGA6, and ITGAL were the prognostic factors in LUAD.…”

Molecular regulatory mechanism of ferroptosis and its role in gastrointestinal oncology: Progress and updates

“…Surgery is the most important therapeutic approach for patients with hepatocellular carcinoma (HCC), but the rate of postoperative recurrence and metastasis is relatively high. Sorafenib is a commonly used chemotherapeutic drug against HCC, but it is difficult to clinically determine the prognosis of HCC and reduce sorafenib resistance[ 69 ]. Shan et al [ 70 ] analyzed two different public HCC databases and found that ubiquitin-like modifier activating enzyme 1 (UBA1) can regulate ferroptosis in HCC cells via the Nrf2 pathway.…”